Table 1 Pazopanib in advanced desmoplastic small round cell tumour
From: Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
Case | Age at onset of pazopanib | Sex | PS | Site of metastases | Starting dose (mg) | Dose reduction | Best response | PFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|---|
1 | 21 | M | 2 | Peritoneum, liver, kidney | 600 | N | PD | 0.5 | 2.1 |
2 | 22 | M | 1 | Peritoneum | 800 | Y | SD | 9.2 | 9.7 |
3 | 47 | M | 1 | Peritoneum, liver | 800 | N | PR | 16.3 | 25.8 |
4 | 21 | M | 1 | Peritoneum, liver | 800 | N | SD | 3.9 | 9.2 |
5 | 30 | M | 0 | Peritoneum, lung, lymph nodes, liver | 800 | Y | PD | 2.5 | 7.4 |
6 | 33 | M | 0 | Peritoneum, liver | 800 | Y | SD | 9.4 | 15.4 |
7 | 20 | M | 1 | Peritoneum, lung, bone | 800 | N | SD | 4.4 | 26 |
8 | 30 | M | 0 | Peritoneum, liver, lymphnodes | 800 | N | SD | 9.9 | 26.7* |
9 | 30 | M | 0 | Peritoneum, liver | 800 | N | PR | 13.1 | 13.8* |